Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Burke Wealth Managament The Focused Growth Strategy 2024 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Burke Wealth Managament The Focused Growth Strategy)

Primary Source Intelligence • Q3 2024 Letter Analysis

Burke Wealth Managament The Focused Growth Strategy Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Burke Wealth Managament The Focused Growth Strategy. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+2.6%

YTD+25.1%

Annualized+14.2%

Digest Analysis

Quick Take

"Manager used weakness to upgrade portfolio quality, selling Blackrock after thesis completion and adding to Crowdstrike and ASML during temporary setbacks."

Executive Summary

Burke Wealth Management's Focused Growth portfolio gained 2.6% in Q3 2024, bringing YTD returns to 25.1%. The manager navigated significant market volatility driven by political upheaval, economic uncertainty, and the Fed's rate cutting cycle initiation. Portfolio companies delivered strong fundamentals with 9 of 20 holdings posting 20%+ earnings growth. Key portfolio moves included selling Blackrock after its thesis played out and the risk-reward profile became less favorable, while increasing positions in Crowdstrike and ASML during their respective declines. The Crowdstrike global IT outage presented a buying opportunity as customer retention remained strong and the company's response was well-received. ASML's weakness from China restrictions and Intel CAPEX cuts was viewed as transitory given their monopoly position in EUV lithography. Looking ahead, the manager expects reduced political uncertainty post-election and continued Fed easing to provide a favorable backdrop for secular growth businesses. The portfolio remains positioned for long-term compounding in high-quality companies with strong competitive advantages.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

High conviction demonstrated through concentrated 20-position portfolio with named, sized holdings. Manager provides detailed thesis explanations for major positions, makes decisive portfolio moves during volatility, and expresses strong confidence in specific companies like ASML's monopoly position and Crowdstrike's recovery prospects. Clear position sizing language and willingness to add during weakness indicates strong conviction.

Growth Outlook

25%

BearishBullish

Bearish (25%)

Manager expresses cautious optimism about markets. Positive on post-election visibility and Fed easing cycle providing favorable backdrop for equities, but acknowledges significant risks including geopolitical unrest, labor disputes, and potential recession concerns from weakening economic growth.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

Portfolio positioning shows selective risk-taking. Manager is actively deploying capital by increasing positions in ASML and Crowdstrike during weakness, while harvesting gains from Blackrock. Maintains concentrated 20-position portfolio in secular growth names, indicating moderate risk appetite.

Capital Deployment

15%

De-riskingDeploying

De-risking (15%)

Moderate deployment activity through portfolio rotation. Manager sold Blackrock position and used proceeds to increase positions in ASML and Crowdstrike. This represents capital rotation rather than net new deployment, as cash levels are not discussed and the activity appears to be funded by sales rather than reducing cash.

Forward Guidance

30%

CautiousExpansionary

Cautious (30%)

Manager indicates selective deployment bias, using market weakness to build positions in high-conviction names. Expects favorable conditions post-election and with Fed easing, but maintains measured approach focused on company-specific opportunities rather than broad market deployment.

Language Signal

20%

BearishBullish

Bearish (20%)

Language is balanced with slight positive tilt. Uses opportunity-focused terms like 'favorable backdrop,' 'strong close to the year,' and 'confidence in business momentum,' but also acknowledges risks, uncertainty, and describes market conditions as having 'harrowing moments' and 'a lot to deal with.'

Perceived Risk

55%

Low RiskElevated

Moderate Risk (55%)

Manager acknowledges multiple meaningful risks including potential 5-10% S&P 500 earnings hit from tax cut expiration, recession concerns from weakening growth, geopolitical unrest, and labor disputes. Describes Q3 as having 'harrowing moments' and market dealing with 'a lot of uncertainty,' indicating moderate risk perception.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

Manager sees selective opportunities in defined areas. Identifies specific attractive situations like Crowdstrike post-outage and ASML during temporary weakness, while noting that strong underlying fundamentals with 9 of 20 holdings posting 20%+ earnings growth. Suggests good opportunity set within secular growth businesses but requires selectivity.

Time Horizon

75%

Short-TermLong-Term

Decade+ (75%)

Multi-year investment horizon evident through focus on secular growth themes, long-term competitive moats, and willingness to hold through short-term volatility. Manager describes building 'long-term position' in ASML and focuses on multi-year trends like AI adoption. No urgency for near-term catalysts, emphasizing patient capital approach to quality compounding.